Abstracts presented for GL-ONC1, its Lead Product Candidate
SAN DIEGO, June 15, 2013 — Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and diagnostics, today announced that it will present two abstracts on its lead product candidate, GL-ONC1, an oncolytic (cancer-killing) viral therapy, at the 2013 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec City, Quebec from June 15 through 18, 2013. The abstracts presented will be:
- “Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresectable, chemotherapy-resistant peritoneal carcinomatosis” will be presented on Tuesday 18 June by the study’s lead investigator, Ulrich Lauer, MD, Department of Gastroenterology & Hepatology, Medical University Hospital, Tuebingen, Germany. This ongoing trial, which is currently recruiting patients, is designed to assess safety, maximum tolerated dose (MTD) and anti-tumor activity of GL-ONC1.
- “Isolate limb perfusion (ILP) with melphalan, tumor necrosis factor-alpha and oncolytic vaccinia virus delays tumor growth and prolongs survival in a rat model of locally advanced extremity sarcoma” will be presented on Sunday 16 June by Michelle Wilkinson of the Institute of Cancer Research in London. In the study, treatment efficacy after ILP with combination of TNF-α, melphalan and GL-ONC1 were evaluated and used to study the locoregional and systemic biodistribution of virus after delivery by ILP. Further evaluation and clinical translation of this model is warranted in a Phase I study which will be conducted I the pre-existing surgical ILP program at The Royal Marsden Hospital.
“GL-ONC1, our leading product candidate, has been well-tolerated and shown encouraging results in a number of Phase I, Ib and Phase I-II clinical trials in the U.S. and Europe against a number of solid tumor cancers. It is based on our novel product platform that delivers therapeutic and diagnostic constructs directly to tumors without harming healthy tissues or cells,” said Dr. Aladar A. Szalay, founder and CEO of Genelux Corporation.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNAs into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit https://genelux.com/
Genelux Forward-Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management’s current beliefs and assumptions founded on the data and information currently available to us. Statements of the company’s progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.